Changing the Face of Longevity Forever™
KLOTHO Therapeutics (KTI™) is a biotechnology company developing a patent-pending Klotho protein that has great potential to redefine society’s experience with aging.
KTI has worldwide patents pending on versions of modified, recombinant Klotho that can be manufactured using standard cell culture technology.
Applications of Klotho Protein
Natural human Klotho is associated with improved cognitive performance in humans. In fact, 25% of the population naturally produces higher levels of Klotho. In these people, executive thinking is measurably better and parts of the brain measurably bigger than the normal population. That is, an 85 year old who has higher levels of Klotho has similar brain size and thinking ability to someone over 10 years younger. Lifespan is affected too. In animal studies, overexpression of Klotho leads to 20-30% longer lives than those with normal Klotho levels.
Klotho plays a major role in kidney disease as much of the Klotho protein circulating in the blood is produced in the kidneys. Klotho levels are known to decline in chronic kidney disease (CKD) and may be an early marker of this disease. Klotho deficiency may be one of the causes for CKD progression and resulting complications including cardiovascular disease. Klotho has also been shown to play a role in acute kidney injury. In animal studies, Klotho reduced the size of the kidney injury and promoted healing.
Klotho also plays a role in cancer, a disease that kills more than 500,000 Americans every year. Several studies show that Klotho levels are decreased in certain types of human tumor cells/tissues and reduced Klotho expression in liver cancer patients was associated with decreased survival. In addition, multiple animal studies have shown that Klotho can improve survival rates, reduce metastasis and reduce cancer cell resistance to chemotherapeutic agents.
Klotho levels are associated with insulin production in human and animal studies. The Centers for Disease Control indicate that >29 million Americans are living with diabetes, and 86 million are living with prediabetes, which significantly increases their risk of type 2 diabetes and other chronic diseases. Human and animal research show that Klotho levels are decreased in the pancreatic islets in diabetics and lack of Klotho is associated with decreased insulin production. When diabetic mice were treated with Klotho for 2 weeks, blood glucose levels declined significantly, accompanied by significant increases in insulin levels.